Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LINDA F STEIN GOLD

Allopathic & Osteopathic Physicians Dermatology

NPI
1619055746
CMS profile
636850
Location
WEST BLOOMFIELD, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$683,931.29

507 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 11; records 51–100 of 507 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LINDA F STEIN GOLD

NPI 1619055746 · CMS profile ID 636850

Allopathic & Osteopathic Physicians / Dermatology

WEST BLOOMFIELD, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 11; records 51–100 of 507 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1619055746?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LINDA F STEIN GOLD, NPI 1619055746, CMS profile ID 636850. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 11; records 51–100 of 507 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1619055746?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). LINDA F STEIN GOLD, NPI 1619055746, CMS profile ID 636850. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 11; records 51–100 of 507 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1619055746?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
LINDA F STEIN GOLD, NPI 1619055746, CMS profile ID 636850, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 11; records 51–100 of 507 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1619055746?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

507 matching records · $683,931.29 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 507 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 507.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $83.3311/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988383479 CMS
Arcutis Biotherapeutics, Inc. $91.1211/14/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044777061 CMS
Arcutis Biotherapeutics, Inc. $6,375.0011/14/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044777097 CMS
Eli Lilly and Company $1,600.0011/14/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031905789 CMS
Galderma Laboratories, L.P. $790.0011/14/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059725987 CMS
AbbVie Inc. $306.2211/12/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999112807 CMS
Dermavant Sciences, Inc. $3,200.0011/10/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991257451 CMS
Arcutis Biotherapeutics, Inc. $240.8011/09/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044777047 CMS
Arcutis Biotherapeutics, Inc. $1,040.7011/09/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044777073 CMS
Arcutis Biotherapeutics, Inc. $280.4411/09/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044777085 CMS
Arcutis Biotherapeutics, Inc. $92.7411/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044777109 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $27.2611/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051617321 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $81.9411/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051617333 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $534.5211/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051617331 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $715.5311/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051617337 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $492.8011/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051617339 CMS
UCB, Inc. $27.5311/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021780975 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $118.2311/02/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051617327 CMS
Arcutis Biotherapeutics, Inc. $1,875.0011/01/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044776875 CMS
E.R. Squibb & Sons, L.L.C. $7,161.0011/01/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016409869 CMS
LEO Pharma Inc. $8,097.5010/25/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053533981 CMS
Lilly USA, LLC $3,200.0010/25/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031776173 CMS
PFIZER INC. $730.0010/25/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049483167 CMS
E.R. Squibb & Sons, L.L.C. $3,038.0010/24/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016409581 CMS
LEO Pharma Inc. $2,002.5010/23/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053533975 CMS
PFIZER INC. $207.2210/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050613745 CMS
Incyte Corporation $52.0810/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044454127 CMS
Arcutis Biotherapeutics, Inc. $75.0510/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044776863 CMS
GENZYME CORPORATION $7,686.0010/19/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049801821 CMS
PFIZER INC. $75.7210/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050645865 CMS
Regeneron Healthcare Solutions, Inc. $33.4010/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999466553 CMS
Lilly USA, LLC $33.7910/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031776177 CMS
Lilly USA, LLC $31.8710/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031787587 CMS
Lilly USA, LLC $34.7710/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061274975 CMS
AbbVie Inc. $800.0010/16/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999112802 CMS
AbbVie Inc. $5.6810/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999112789 CMS
AbbVie Inc. $9.5210/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999112794 CMS
AbbVie Inc. $45.5810/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999112797 CMS
Galderma Laboratories, L.P. $8,000.0010/13/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059725983 CMS
Galderma Laboratories, L.P. $8,000.0010/13/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059725985 CMS
Incyte Corporation $5.4910/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044454063 CMS
LEO Pharma AS $50.0010/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053448329 CMS
LEO Pharma AS $10.6010/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053448333 CMS
LEO Pharma Inc. $12.6310/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053533969 CMS
E.R. Squibb & Sons, L.L.C. $85.8510/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016409587 CMS
Dermavant Sciences, Inc. $78.0610/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991257447 CMS
Incyte Corporation $26.4310/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044454055 CMS
Janssen Global Services, LLC $26.1610/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988242371 CMS
Janssen Global Services, LLC $5.4610/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988242383 CMS
PFIZER INC. $10.5510/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049358887 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $293,980.81 280
PY2020 $320,718.95 185
PY2021 $338,649.61 176
PY2022 $407,582.12 280
PY2023 $683,931.29 507
PY2024 $591,481.84 465
PY2025 $630,245.89 458

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $5,306.44 3
PY2025 Principal investigator $917,754.64 114
PY2024 Recipient $12,888.98 7
PY2024 Principal investigator $1,070,129.89 464
PY2023 Recipient $12,090.00 15
PY2023 Principal investigator $637,486.22 332
PY2022 Recipient $8,000.00 5
PY2022 Principal investigator $297,560.40 90
PY2021 Recipient $5,522.57 6
PY2021 Principal investigator $435,341.26 75
PY2020 Recipient $13,595.40 11
PY2020 Principal investigator $469,132.33 114
PY2019 Recipient $21,312.81 8
PY2019 Principal investigator $434,758.39 85

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

117 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $3,537.36 12/31/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects with Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy No dispute reported 06/30/2026 1202412418
Principal investigator 1 ABBVIE INC. $1,529.40 12/31/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata No dispute reported 06/30/2026 1202412422
Principal investigator 1 PFIZER INC. $3,567.49 12/31/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228744320
Principal investigator 1 Janssen Research & Development, LLC $4,996.00 12/25/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175361317
Principal investigator 1 SANOFI US SERVICES INC. $2,000.00 12/22/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226124316
Principal investigator 1 Incyte Corporation $2,707.00 12/19/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240479983
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $20,152.48 12/19/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223266713
Principal investigator 1 PFIZER INC. $3,963.57 12/17/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228725724
Principal investigator 1 ABBVIE INC. $5,991.00 12/11/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202412408
Principal investigator 1 ABBVIE INC. $6,902.00 12/11/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202412411
Principal investigator 1 Incyte Corporation $2,856.00 12/11/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240479987
Principal investigator 1 SANOFI US SERVICES INC. $13,923.00 12/08/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226124306
Principal investigator 1 ABBVIE INC. $3,353.08 12/04/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202412392
Principal investigator 1 ABBVIE INC. $4,307.40 12/04/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202412396
Principal investigator 1 Incyte Corporation $2,500.00 12/04/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240479980
Principal investigator 1 Incyte Corporation $6,000.00 12/04/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240479991
Principal investigator 1 Janssen Research & Development, LLC $4,872.00 12/01/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175361210
Principal investigator 1 ABBVIE INC. $3,940.00 11/20/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202412378
Principal investigator 1 ABBVIE INC. $17,450.00 11/20/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202412381
Principal investigator 1 ABBVIE INC. $3,940.00 11/20/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202412384
Principal investigator 1 ABBVIE INC. $1,835.38 11/05/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202412363
Principal investigator 1 ABBVIE INC. $4,031.03 11/05/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202412366
Principal investigator 1 SANOFI US SERVICES INC. $5,429.00 11/04/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226124303
Principal investigator 1 Janssen Research & Development, LLC $5,904.00 11/03/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175361369
Principal investigator 1 Incyte Corporation $2,707.00 10/29/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240479975
Principal investigator 1 SANOFI US SERVICES INC. $18,938.00 10/27/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226124288
Recipient GENZYME CORPORATION $500.00 10/24/2025 Covered Recipient Physician A Phase IIb, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Dose Ranging Study of a Subcutaneous Anti-OX40L Monoclonal Antibody (KY1005) in Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226108636
Principal investigator 1 Janssen Research & Development, LLC $7,592.00 10/24/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175361168
Principal investigator 1 Galderma Laboratories, L.P. $2,763.38 10/17/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1234511776
Principal investigator 1 ABBVIE INC. $2,467.07 10/09/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202412336
Principal investigator 1 ABBVIE INC. $2,573.42 10/09/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202412340
Principal investigator 1 ABBVIE INC. $3,939.76 10/09/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202412343
Principal investigator 1 PFIZER INC. $1,791.57 10/04/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228730615
Principal investigator 1 Janssen Research & Development, LLC $4,872.00 09/29/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175361427
Principal investigator 1 PFIZER INC. $3,567.49 09/26/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228758729
Principal investigator 1 Galderma Laboratories, L.P. $1,663.75 09/24/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1234511761
Principal investigator 1 Galderma Laboratories, L.P. $1,000.00 09/24/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1234511769
Principal investigator 1 Incyte Corporation $2,707.00 09/23/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240479971
Principal investigator 1 Amgen Inc. $2,027.96 09/22/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) No dispute reported 06/30/2026 1246637742
Principal investigator 1 Galderma Laboratories, L.P. $7,115.00 09/10/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1234511750
Principal investigator 1 Janssen Research & Development, LLC $5,059.00 09/08/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175361353
Principal investigator 1 SANOFI US SERVICES INC. $13,715.00 09/08/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226124249
Principal investigator 1 ABBVIE INC. $1,835.38 09/04/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202412294
Principal investigator 1 ABBVIE INC. $7,711.44 09/04/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202412297
Principal investigator 1 ABBVIE INC. $2,467.07 09/03/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202412287
Principal investigator 1 Incyte Corporation $3,155.00 08/26/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240479967
Principal investigator 1 SANOFI US SERVICES INC. $18,600.00 08/25/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226124270
Principal investigator 1 Incyte Corporation $790.00 08/21/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240479963
Principal investigator 1 ABBVIE INC. $5,000.00 08/19/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202412267
Recipient Amgen Inc. $3,866.44 08/08/2025 Covered Recipient Physician Early initiation of Apremilast. No dispute reported 06/30/2026 1246637068
Principal investigator 1 ABBVIE INC. $2,615.38 08/06/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202412253
Principal investigator 1 ABBVIE INC. $7,840.93 08/06/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202412259
Principal investigator 1 SANOFI US SERVICES INC. $9,010.00 08/04/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226124240
Principal investigator 1 Janssen Research & Development, LLC $9,351.00 08/01/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175361137
Principal investigator 1 Incyte Corporation $3,621.00 07/31/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240479956
Principal investigator 1 Janssen Research & Development, LLC $11,300.00 07/29/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175231938
Principal investigator 1 PFIZER INC. $3,505.14 07/29/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228782607
Principal investigator 1 Janssen Research & Development, LLC $25,318.00 07/28/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175361224
Principal investigator 1 Incyte Corporation $4,471.00 07/22/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240479959
Principal investigator 1 PFIZER INC. $1,595.27 07/17/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228773202
Principal investigator 1 SANOFI US SERVICES INC. $19,227.00 07/14/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226124218
Principal investigator 1 SANOFI US SERVICES INC. $4,987.00 07/14/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226124220
Principal investigator 1 ABBVIE INC. $2,016.68 07/08/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202412219
Principal investigator 1 ABBVIE INC. $2,312.50 07/02/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202412212
Principal investigator 1 Galderma Laboratories, L.P. $1,000.00 07/02/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1234511730
Principal investigator 1 Galderma Laboratories, L.P. $1,000.00 07/02/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1234511739
Principal investigator 1 SANOFI US SERVICES INC. $38,042.00 06/16/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226124209
Principal investigator 1 ABBVIE INC. $2,312.50 06/11/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202412200
Principal investigator 1 SANOFI US SERVICES INC. $9,379.00 06/09/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226124204
Principal investigator 1 Incyte Corporation $500.00 06/05/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240479942
Principal investigator 1 Incyte Corporation $8,000.00 06/05/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240479946
Principal investigator 1 Incyte Corporation $17,800.00 06/05/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240479952
Principal investigator 1 ABBVIE INC. $1,692.64 06/03/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202412188
Principal investigator 1 ABBVIE INC. $2,110.28 06/03/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202412192
Principal investigator 1 PFIZER INC. $2,136.07 05/30/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228719989
Principal investigator 1 Janssen Research & Development, LLC $21,678.00 05/26/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175361129
Principal investigator 1 PFIZER INC. $98.80 05/16/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228782445
Principal investigator 1 SANOFI US SERVICES INC. $7,916.10 05/12/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226124197
Principal investigator 1 Eli Lilly and Company $6,120.60 05/08/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187871339
Principal investigator 1 ABBVIE INC. $2,640.34 05/07/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202412172
Principal investigator 1 ABBVIE INC. $6,031.96 05/07/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202412175
Principal investigator 1 PFIZER INC. $10,798.20 05/03/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228719925
Principal investigator 1 Janssen Research & Development, LLC $3,500.00 04/28/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175233096
Principal investigator 1 ABBVIE INC. $5,440.00 04/24/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202412161
Principal investigator 1 Incyte Corporation $10,887.20 04/18/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema No dispute reported 06/30/2026 1240475125
Principal investigator 1 Incyte Corporation $201.60 04/18/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema No dispute reported 06/30/2026 1240475128
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $7,492.00 04/09/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis No dispute reported 06/30/2026 1236001070
Principal investigator 1 ABBVIE INC. $1,692.38 04/03/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202412141
Principal investigator 1 ABBVIE INC. $2,263.49 04/03/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202412145
Principal investigator 1 ABBVIE INC. $7,690.93 04/03/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202412149
Principal investigator 1 SANOFI US SERVICES INC. $10,577.00 04/02/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226124165
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $14,736.40 03/27/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Phase 3B/4, Multicenter, Randomized, Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Moderate-to-severe Scalp Psoriasis (PSORIATYK SCALP) No dispute reported 06/30/2026 1236001072
Principal investigator 1 Incyte Corporation $1,351.81 03/27/2025 Non-covered Recipient Entity
HENRY FORD MEDICAL CENTER-NEW CENTER ONE
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1240538075
Principal investigator 1 Janssen Research & Development, LLC $268.00 03/24/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175232574
Principal investigator 1 Janssen Research & Development, LLC $608.00 03/24/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175232755
Principal investigator 1 Janssen Research & Development, LLC $4,542.00 03/24/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175361329
Principal investigator 1 PFIZER INC. $1,595.27 03/22/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228795692
Principal investigator 1 Janssen Research & Development, LLC $3,500.00 03/21/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175232442
Principal investigator 1 SANOFI US SERVICES INC. $14,657.10 03/10/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226124161
Principal investigator 1 ABBVIE INC. $11,137.28 03/07/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202412094
Principal investigator 1 PFIZER INC. $2,234.87 03/04/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228797566
Principal investigator 1 Janssen Research & Development, LLC $3,500.00 03/03/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175232634
Principal investigator 1 Janssen Research & Development, LLC $6,813.00 03/03/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175361405
Principal investigator 1 UCB SA $31,696.20 03/03/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) No dispute reported 06/30/2026 1246658354
Principal investigator 1 SANOFI US SERVICES INC. $20,743.10 02/24/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226124111
Principal investigator 1 PFIZER INC. $6,584.63 02/11/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228758292
Principal investigator 1 Janssen Research & Development, LLC $17,259.00 02/10/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175361247
Principal investigator 1 ABBVIE INC. $2,663.11 02/06/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202412028
Principal investigator 1 ABBVIE INC. $2,627.86 02/06/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202412032
Principal investigator 1 UCB SA $18,939.60 02/03/2025 Non-covered Recipient Entity
Henry Ford Behavioral Health Hospital
MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) No dispute reported 06/30/2026 1246656335
Recipient PFIZER INC. $940.00 01/30/2025 Covered Recipient Physician ABROCITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228751356
Principal investigator 1 Janssen Research & Development, LLC $574.00 01/27/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175232989
Principal investigator 1 Incyte Corporation $11,387.05 01/23/2025 Non-covered Recipient Entity
HENRY FORD MEDICAL CENTER-NEW CENTER ONE
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1240538070
Principal investigator 1 Amgen Inc. $138,352.60 01/21/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246637744
Principal investigator 1 Janssen Research & Development, LLC $3,600.00 01/16/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175232138
Principal investigator 1 ABBVIE INC. $2,091.74 01/02/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202412002
Principal investigator 1 Amgen Inc. $40,374.55 01/02/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis No dispute reported 06/30/2026 1246637746